Login / Signup

Renal Response Outcomes of the EuroLupus and NIH Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus Nephritis.

Christine S WangRebecca E SadunWenru ZhouKristen R MillerLaura PyleStacey P ArdoinChristine BachaEmily HauseJoyce Hui-YuenNicole LingMaria PereiraMeredith RiebschlegerKelly Rouster-StevensAliese SarkissianJulia ShalenWilliam Daniel SoulsbyMarinka TwiltEveline Y WuLaura B LewandowskiScott E WenderferJennifer C Coopernull null
Published in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Our study failed to demonstrate a benefit of the NIH regimen over the EuroLupus CYC regimen in childhood-onset proliferative LN. However, future prospective outcome studies are needed.
Keyphrases
  • early life
  • low dose
  • childhood cancer
  • high dose
  • current status
  • type diabetes
  • young adults
  • skeletal muscle
  • case control
  • insulin resistance
  • glycemic control